Dr Waymon Ray Hinson, PHD | |
1049 N 3rd St, Suite 505, Abilene, TX 79601-5833 | |
(325) 672-8883 | |
(325) 675-5833 |
Full Name | Dr Waymon Ray Hinson |
---|---|
Gender | Male |
Speciality | Marriage & Family Therapist |
Location | 1049 N 3rd St, Abilene, Texas |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1952302671 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103T00000X | Psychologist | 22909 (Texas) | Primary |
106H00000X | Marriage & Family Therapist | 002784 (Texas) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Waymon Ray Hinson, PHD 1049 N 3rd St, Suite 505, Abilene, TX 79601-5833 Ph: (325) 672-8883 | Dr Waymon Ray Hinson, PHD 1049 N 3rd St, Suite 505, Abilene, TX 79601-5833 Ph: (325) 672-8883 |
News Archive
The bacterium that causes whooping cough, Bordetella pertussis, has changed in Australia - most likely in response to the vaccine used to prevent the disease - with a possible reduced effectiveness of the vaccine as a result, a new study shows.
Promethera Biosciences SA, a world-leading cell therapy and regenerative medicine company targeting liver diseases, today announced the presentation of new preclinical NASH-Fibrosis data from its proprietary HepaStem program, demonstrating a beneficial effect of HepaStem in a nonalcoholic steatohepatitis (NASH) mouse model and confirming Hepastem's unique and multifaceted mode of action.
In a New York City metro-area first, a 93-year-old Bronx man underwent implantation of a new stent graft at NewYork-Presbyterian Hospital, the only center on the Eastern Seaboard with access to this investigational device. The new stent graft was implanted under an FDA-approved clinical trial protocol.
Radiotherapy for cancer involves exposing the patient or their tumor more directly to ionizing radiation, such as gamma rays or X-rays.
CryoCor, Inc. has announced that the United States Patent and Trademark Office (USPTO) has declared a patent interference between a patent application exclusively licensed by CryoCor and two patents held by CryoCath Technologies Inc.
› Verified 1 days ago